Shares of pharma major Wockhardt today climbed by about 20 per cent, on reports that the company might go for corporate debt restructuring settlement.
Reacting positively to the move, the stock soared by about 20 per cent to touch a year-high of Rs 223.95 on the Bombay Stock Exchange in the mid-session.
On the National Stock Exchange as well, the scrip shot-up by over 20 per cent and was trading at Rs 224.65.
In terms of volume, over 60 lakh shares of the pharma firm changed hands on the two exchanges in the afternoon trade.
According to reports, the company may replace the existing Foreign Currency Convertible Bonds (FCCBs) with the new ones. It may issue FCCBs worth $75.08 million and increase the authorised capital from Rs 925 crore to Rs 1,125 crore.
The need for a corporate debt restructuring often arises when a company is going through financial hardship and is having difficulty in meeting its debt payment obligations.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
